The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants and monoclonal antibodies are approved and recommended to reduce inflammation in multiple sclerosis. The complex nature of disease with its unique individual patient course renders variable clinical outcomes in different patients. Although there is no cure for multiple sclerosis, the currently available therapeutics modify the disease course, accelerate recovery from attacks, and help in managing symptoms.
Market Dynamics
The major factors driving growth of the multiple sclerosis therapeutics market include rise in research and development ultimately leading to the launch of novel drug candidates and the rising prevalence of the condition in children. For instance, in 2014, Plegridy (peginterferon beta-1a) manufactured by Biogen, a disease modifying therapy was approved for the long-term treatment of relapsing forms of multiple sclerosis. According to Multiple Sclerosis Society, approximately five to ten per cent of people with MS experienced their first symptoms before the age of 16. However, the inability of drugs to prevent disease progression and disability, side effects of the approved drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), a viral disease of the brain are the factors hindering market growth.
Key features of the study:
This report provides in-depth analysis of multiple sclerosis therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global multiple sclerosis therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Novartis AG, Teva Pharmaceuticals Industries Ltd., Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, market expansion, and marketing tactics
The global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the multiple sclerosis therapeutics market
Detailed Segmentation:
Global Multiple Sclerosis Therapeutics Market, By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
Global Multiple Sclerosis Therapeutics Market, By Route of Administration:
Oral
Injection
Global Multiple Sclerosis Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Global Multiple Sclerosis Therapeutics Market, By Geography:
North America
By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
U.S.
Canada
Latin America
By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Novartis AG*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Teva Pharmaceuticals Industries Ltd.
Sanofi S.A.
Bayer AG
Pfizer, Inc.
Biogen Idec
Merck & Co., Inc.
AbbVie, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Drug Class
? Market Snippet, By Route of Administration
? Market Snippet, By Distribution Channel
? Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Restraints
? Market Opportunities
? Market Trends
o Regulatory Scenario
o Reimbursement Scenario
o Alternative Therapies
o Pipeline Analysis
o Supply Chain Analysis
o PEST Analysis
o Epidemiology
4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Beta Interferon
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Corticosteroids
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Monoclonal Antibodies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Antineoplastic Agents
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Others
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Oral
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Injection
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Hospital Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Retail Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o E-Commerce
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
7. Global Multiple Sclerosis Therapeutics Market, By Region, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, For Regions, 2017 - 2025
o North America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? U.S.
? Canada
o Latin America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Brazil
? Mexico
? Rest of Latin America
o Europe
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Germany
? U.K.
? France
? Italy
? Spain
? Russia
? Rest of Europe
o Asia Pacific
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? China
? India
? Japan
? Australia
? South Korea
? ASEAN
? Rest of APAC
o Middle East
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? GCC
? Israel
? Rest of Middle East
o Africa
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? South Africa
? Central Africa
? North Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? Novartis AG*
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Teva Pharmaceuticals Industries Ltd.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Sanofi S.A.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Bayer AG
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Pfizer, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Biogen Idec
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Merck & Co., Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? AbbVie, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 35 market data tables and 40 figures on "Multiple Sclerosis Therapeutics Market - Global forecast to 2025".
Request Discount 
Inquire Before Buy
